Markets
Xeris Biopharma Stock Soars 10.32% In Friday Trading, Adding $246 Million In Market Value
The drugmaker entered Friday up 67% this year, with a higher revenue forecast and plans for a late-stage thyroid trial.
XERS
Xeris Biopharma Holdings (XERS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Xeris Raises Sales Forecast To $395–$405 Million As Recorlev Revenue Surges 93%
The drugmaker also lifted its 2030 revenue outlook to more than $1 billion, from approximately $750 million.
Earnings
Xeris Sees Recorlev Reaching $1 Billion In Annual Net Revenue 3 To 4 Years Sooner
CEO John Shannon also lifted the 2030 total revenue outlook to more than $1 billion from $750 million after a 44% jump in quarterly revenue.
SEC Filings
Xeris Biopharma Adds Ex-Viatris Emerging Markets Chief Menassie Taddese To Its Board
The drugmaker expanded its board from eight to nine seats and put the new director on its Audit Committee.
SEC Filings
Xeris Files Two Patent Suits Over Generic KEVEYIS, Citing Newly Granted '502 Patent
Xeris Biopharma's 8-K names seven defendants in two New Jersey federal cases and seeks an injunction plus damages.